On January 31, A-share listed Daan Gene (002030) released the 2022 full-year performance forecast. The company expects a significant rise from January to December 2022, the net profit attributable to shareholders of the listed company is 5.1 to 5.8 billion, the net profit increased by 40.95% to 60.30% year-on-year, and the basic earnings per share is expected to be CNY 3.6339 to 4.1327 yuan.

Daan Gene made the above forecast based on the following reasons: 

The main reasons for the same directional increase in the net profit attributable to shareholders of the listed company rises in 2022 are: 

During the reporting period, as one of the suppliers of COVID-19 nucleic acid diagnostic products in China, Daan Gene enabled sufficient production capacity for COVID-19 nucleic acid test products with its self-developed and integrated whole industry chain platform, made every effort to ensure market supply, and continued to strengthen the development and layout of global markets. The constant demands for COVID-19 nucleic acid test kits and nucleic acid test instruments and related consumables had a positive impact on the company's performance.

The sector of Daan Gene is medical devices.

About Daan Gene

Daan Gene Co., Ltd. is in the front ranks among world's molecular diagnosis companies with its expertise in the research, development and application of fluorescent PCR assay technology, production and sales of fluorescent PCR kits and medical equipment, and provision of clinical testing services. 

The company has become a leading enterprise in China’s molecular diagnostic reagent industry, with the "Daan Gene" brand, which is the market leader in the industry, as well as the "Darui Biotech" brand and "Zhongshan Bio-tech" with regional advantage.